首页    期刊浏览 2024年11月07日 星期四
登录注册

文章基本信息

  • 标题:Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment
  • 本地全文:下载
  • 作者:Gilbert Spizzo ; Uwe Siebert ; Guenther Gastl
  • 期刊名称:Cost Effectiveness and Resource Allocation
  • 印刷版ISSN:1478-7547
  • 电子版ISSN:1478-7547
  • 出版年度:2019
  • 卷号:17
  • 期号:1
  • 页码:1-5
  • DOI:10.1186/s12962-019-0191-6
  • 出版社:BioMed Central
  • 摘要:Tumor profiling is increasingly used in advanced cancer patients to define treatment options, especially in refractory cases where no standard treatment is available. Caris Molecular Intelligence (CMI) is a multiplatform tumor profiling service that is comprehensive of next-generation sequencing (NGS) of DNA and RNA, immunohistochemistry (IHC) and in situ hybridisation (FISH). The aim of this study is to compare costs of CMI-guided treatment with prior or planned treatment options in correlation with outcome results. Retrospective data from five clinical trials were collected to define the treatment decision prior to the receipt of the CMI report (n = 137 patients). A systematic review of treatment data from 11 clinical studies of CMI (n = 385 patients) allowed a comparison of planned vs actual (n = 137) and prior vs actual (n = 229) treatment costs. Treatment plan was changed in 88% of CMI-profiled cases. The actual CMI guided treatment cost per cycle was £995 in 385 treated patients. Planned treatment costs were comparable to actual treatment costs (£979 vs £945; p = 0.7123) and prior treatment costs were not significantly different to profiling-guided treatments (£892 vs £850; p = 0.631). Caris Molecular Intelligence guided treatment cost per cycle was in the range of prior or planned treatment cost/cycle. Due to beneficial overall survival the additional cost of performing CMI’s multiplatform testing to the treatment costs seems to be cost-effective.
  • 关键词:CARIS multiplatform;Molecular profiling;Cost-effectiveness;Cancer treatment
国家哲学社会科学文献中心版权所有